Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and UCL to pioneer research into Parkinson's disease
Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's disease.
Vets to explore the possibilities of future prevention and treatment.

A pioneering study into the causes and progression of Parkinson's disease is to be carried out by the Royal Veterinary College (RVC) in collaboration with University College London (UCL).

The news follows a $7 million grant from Aligning Science Across Parkinson's (ASAP), an initiative that fosters collaboration and resources to better understand the underlying causes of this debilitating disease.

Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's. Specifically, the team will investigate the role of the LRRK2 gene - one of the most common genetic causes of the disease and a priority drug target.

Dr Patrick Lewis, Professor of Neuroscience at the RVC, said: “The Aligning Science Across Parkinson’s foundation grants represents a new way of approaching research into Parkinson’s, with the clear goal of accelerating progress in our understanding of this disorder. It is a real privilege to be involved in this initiative.”

Parkinson's is a progressive brain disorder that causes slowness, stiffness, tremors and walking and balance problems. The condition affects more than 130,000 people in the UK alone, and the only current available treatments help to alleviate symptoms, but not slow progression of the disease.

Professor Jonathan Elliott, vice-principal (Research and Innovation) at the RVC, said: “The RVC is delighted to be part of this large collaborative effort to advance treatments for Parkinson’s Disease. Neurodegenerative conditions significantly impact on the quality of life of our ageing human population in the UK and Professor Lewis’ role in this collaboration is exciting in its potential to uncover new drug targets to slow progressive loss of functioning neurons."

Become a member or log in to add this story to your CPD history

BSAVA partners with BVA Live 2026

News Story 1
 BSAVA is to partner with BVA Live (11-12 June 2026) to champion clinical research.

The organisation will be supporting BVA Live's Clinical Abstracts programme, showcasing selected abstracts of veterinary research throughout the event.

The clinical abstracts can be on any small animal veterinary subject, and must be based on research undertaken in industry, practice or academia. Abstracts can be presented in poster or oral formats.

Submissions will open on 15th December 2025, and close on 6th March 2026. You can register interest here

Click here for more...
News Shorts
Nominations open for RCVS and VN Council elections

The nomination period for the 2026 RCVS Council and VN Council elections is now open, with three veterinary surgeon seats and two veterinary nurse seats available.

Prospective candidates can download an information pack and nomination form from the RCVS website. Individuals can nominate themselves for the elections, with the results to be announced in the spring.

Clare Paget, the recently appointed RCVS Registrar and elections returning officer, said: "If you want to play your part in influencing and moulding how the professions are regulated, and making key decisions on matters of great importance to your peers, the public and animal health and welfare, please consider standing for RCVS Council or VN Council next year."

Nominations close at 5pm on Saturday, 31 January 2026.